Cite
Faybusovich P, Lim J, Ioffreda MD, et al. Mepolizumab for treating systemic allergic dermatitis with hypereosinophilia likely secondary to a nickel/cobalt-containing coronary artery stent. Contact Dermatitis. 2021;doi: 10.1111/cod.13984.
Faybusovich, P., Lim, J., Ioffreda, M. D., & Al-Shaikhly, T. (2021). Mepolizumab for treating systemic allergic dermatitis with hypereosinophilia likely secondary to a nickel/cobalt-containing coronary artery stent. Contact dermatitis, . https://doi.org/10.1111/cod.13984
Faybusovich, Paul, et al. "Mepolizumab for treating systemic allergic dermatitis with hypereosinophilia likely secondary to a nickel/cobalt-containing coronary artery stent." Contact dermatitis vol. (2021). doi: https://doi.org/10.1111/cod.13984
Faybusovich P, Lim J, Ioffreda MD, Al-Shaikhly T. Mepolizumab for treating systemic allergic dermatitis with hypereosinophilia likely secondary to a nickel/cobalt-containing coronary artery stent. Contact Dermatitis. 2021 Oct 01; doi: 10.1111/cod.13984. Epub 2021 Oct 01. PMID: 34596911.
Copy
Download .nbib